Goldman Sachs Sticks to Their Hold Rating for Kodiak Sciences (KOD)

Goldman Sachs analyst Andrea Tan maintained a Hold rating on Kodiak Sciences (KODResearch Report) today and set a price target of $9.00. The company’s shares opened today at $10.90.

According to TipRanks, Tan is an analyst with an average return of -13.3% and a 25.00% success rate. Tan covers the Healthcare sector, focusing on stocks such as Kodiak Sciences, Codiak BioSciences, and Insmed.

Currently, the analyst consensus on Kodiak Sciences is a Hold with an average price target of $10.33.

See today’s best-performing stocks on TipRanks >>

KOD market cap is currently $577.2M and has a P/E ratio of (1.85).

Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of KOD in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Kodiak Sciences, Inc. is a a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline include KSI-301 for wet AMD; KSI-301 for diabetic eye disease; KSI-501 for DME and uveitis; KSI-201 for resistant wet AMD; and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Read More on KOD:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More